Trial site
Kochi Medical School Hospital
Nankoku, Kochi 783-8505, JapanNot linked to an institution yet
- 13running trials
- 2closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 1/21 trial
- Status
- Active, not recruiting7 trials
- Recruiting6 trials
- Completed2 trials
- Lead sponsor
- Loxo Oncology, Inc.4 trials
- Bayer1 trial
- BeOne Medicines1 trial
- Bristol-Myers Squibb1 trial
- Ferring Pharmaceuticals1 trial
- and 7 more
Running trials
Recruiting
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
NCT07222566· Phase 3· Pfizer· Source
Recruiting
A Study of Vortioxetine in Japanese Pediatric Patients With Major Depressive Disorder
NCT07204314· Phase 3· Takeda· Source
Recruiting
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
NCT06973187· Phase 3· BeOne Medicines· Source
Contact: Study Director
Active, not recruiting
A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07023341· Phase 3· Bayer· Source
Recruiting
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386· Phase 3· Bristol-Myers Squibb· Source
Contact: TOSHIYUKI KOZUKI, Site 0444
Recruiting
Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
NCT06510374· Phase 3· Ferring Pharmaceuticals· Source
Contact: Ferring Pharmaceuticals
Active, not recruiting
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445· Phase 3· Incyte Corporation· Source
Recruiting
Early Treatment With a Sodium-glucose Co-transporter 2 Inhibitor in High-risk Patients With Acute Heart Failure
NCT05392764· Phase 3· Juntendo University· Source
Contact: Toru Kubo
Active, not recruiting
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis
NCT05070858· Phase 3· Regeneron Pharmaceuticals· Source
Active, not recruiting
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT05023980· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
NCT04965493· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
NCT04666038· Phase 3· Loxo Oncology, Inc.· Source
Active, not recruiting
Japanese Idiopathic Interstitial Pneumonias Registry
NCT03041623· North East Japan Study Group· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error